12:00 AM
Oct 13, 2004
 |  BC Extra  |  Financial News

MGI reports earnings

MOGN reported third quarter revenue of $55.5 million, up from $21.2 million in the same period in 2003. Sales of Aloxi palonosetron to prevent chemotherapy-induced nausea and vomiting were $47.6 million, up...

Read the full 141 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >